Verastem (United States)

Recent papers from Verastem (United States)

1. FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non–small cell lung cancerScience Translational Medicine · 2026
2. Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibitionCancer Discovery · 2026
3. Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201Gynecologic Oncology · 2026
4. Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumorsJournal of Clinical Investigation · 2026
5. Abstract LB197: VS-7375, a non-covalent dual ON/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancerCancer Research · 2026
6. Abstract LB183: Strong durable tumor regressions with the KRASG12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRASG12D-mutant pancreatic cancerCancer Research · 2026
7. Abstract 7100: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agentsCancer Research · 2026
8. Abstract 2948: A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition.Cancer Research · 2026
9. Numerical simulations, scaling analysis, surrogate experiments, and analytical model of the dynamics of microorganisms under creeping flow in a rotating bioreactorPhysics of Fluids · 2026
10. NFS-02. Efficacy of the RAF/MEK clamp avutometinib in combination with the mTOR inhibitor everolimus in NF1-associated malignant peripheral nerve sheath tumor modelsNeuro-Oncology Pediatrics · 2025
11. Abstract PR007: Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agentsCancer Research · 2026
12. A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionOncogene · 2025
13. Abstract A086: FAK inhibition improves CD40 agonist immunotherapy response and reduces MAPK signaling in pancreatic ductal adenocarcinomaCancer Research · 2025
14. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase InhibitorInternational Journal of Molecular Sciences · 2025
15. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Journal of Clinical Oncology · 2025
16. Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastasesCell Reports Medicine · 2025
17. A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition2024
18. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapyScience Translational Medicine · 2024
19. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancerInternational Journal of Gynecological Cancer · 2024
20. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancerCancer Medicine · 2024